Summit Therapeutics Stock Forecast, Price & News

Summit Therapeutics (NASDAQ:SMMT) Frequently Asked Questions

Is Summit Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Summit Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SMMT, but not buy additional shares or sell existing shares.
View analyst ratings for Summit Therapeutics or view top-rated stocks.

How has Summit Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Summit Therapeutics' stock was trading at $1.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SMMT stock has increased by 21.2% and is now trading at $2.29.
View which stocks have been most impacted by COVID-19.

Are investors shorting Summit Therapeutics?

Summit Therapeutics saw a increase in short interest in the month of December. As of December 15th, there was short interest totaling 514,600 shares, an increase of 26.3% from the November 30th total of 407,300 shares. Based on an average daily volume of 170,000 shares, the short-interest ratio is presently 3.0 days. Approximately 2.0% of the company's shares are short sold.
View Summit Therapeutics' Short Interest.

When is Summit Therapeutics' next earnings date?

Summit Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Summit Therapeutics.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.09. The company earned $6.12 million during the quarter. Summit Therapeutics had a negative net margin of 424.58% and a negative trailing twelve-month return on equity of 82.11%.
View Summit Therapeutics' earnings history.

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the following people:

• Mr. Robert W. Duggan, Exec. Chairman & CEO (Age 77) (LinkedIn Profile)
• Mr. Michael Paul Donaldson, Chief Financial Officer (Age 44, Pay $296.2k)
• Dr. Mahkam Zanganeh M.B.A., D.D.S., MBA, COO & Director (Age 51, Pay $459.38k)
• Prof. Dame Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 71)
• Dr. David Jonathan Powell, Chief Scientific Officer (Age 51)
• Ms. Michelle Avery, Director of Investor Relations
• Mr. Dave Gancarz, Head of Investor Relations & Corp. Strategy
• Ms. Christine Armstrong, VP of Marketing?
• Mr. Campbell Hair, Head of HR?
• Dr. Jonathon Tinsley, Chief Scientific Officer of DMD (Age 62)

Who are some of Summit Therapeutics' key competitors?

Some companies that are related to Summit Therapeutics include Northwest Biotherapeutics (NWBO), uniQure (QURE), Kura Oncology (KURA), GH Research (GHRS), Centessa Pharmaceuticals (CNTA), ADVANZ PHARMA (CXRXF), Gossamer Bio (GOSS), MacroGenics (MGNX), Syndax Pharmaceuticals (SNDX), Phibro Animal Health (PAHC), Endo International (ENDP), PMV Pharmaceuticals (PMVP), Vanda Pharmaceuticals (VNDA), Tango Therapeutics (TNGX) and Arcutis Biotherapeutics (ARQT).
View all of SMMT's competitors.

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), (CATB), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP).

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

How do I buy shares of Summit Therapeutics?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $2.29.

How much money does Summit Therapeutics make?

Summit Therapeutics has a market capitalization of $223.77 million and generates $20.17 million in revenue each year. The company earns $-52.70 million in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Summit Therapeutics have?

Summit Therapeutics employs 80 workers across the globe.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is www.summitplc.com.

Where are Summit Therapeutics' headquarters?

Summit Therapeutics is headquartered at 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 617-514-7149, via email at [email protected], or via fax at 44-12-3544-3999.